Eplerenone. Antihypertensive, treatment of heart failure, aldosterone antagonist

Drugs of the Future

Volumn 24, Issue 5, 1999, Pages 488-501

  Rabasseda, X ^a   Silvestre, J ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

15BETA,16BETA METHYLENEMEXRENONE; 9,11ALPHA EPOXYPRORENONE; 9,11ALPHA EPOXYSPIRONOLACTONE; ALDOSTERONE ANTAGONIST; CANRENONE; EPLERENONE; EPOXYPRORENONE; EPOXYSPIRONOLACTONE; GLUCOCORTICOID RECEPTOR; JP 97071586; MESPIRENONE; METYRAPONE; MINERALOCORTICOID RECEPTOR; SPIRONOLACTONE; SPIRORENONE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ENDOCRINE DISEASE; HEART FAILURE; HUMAN; HYPERTENSION; NONHUMAN; ORAL DRUG ADMINISTRATION; RECEPTOR AFFINITY; REVIEW;

EID: 0032974550     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.05.526908     Document Type: Review

References (24)

1. Ng, J.S., Wang, P.T., Baez, J.A. et al. (G.D. Searle & Co.). Process for preparation of 7α-carboxyl 9,11-epoxy steroids and intermediates useful therein and a general process for the epoxidation of olefinic double bonds. WO 9721720.
2. Ng, J.S., Liu, C., Anderson, D.K. et al. (G.D. Searle & Co.). Processes for the preparation of 9,11-epoxy steroids and intermediates useful therein. WO 9825948.
3. Grob, J., Boillaz, M., Schmidlin, J. et al. Steroidal, aldosterone antagonists: Increased selectivity of 9α,11-epoxy derivatives. Helv Chim Acta 1997, 80: 566-85.
4. Grob, J., Kalvoda, J. (Ciba Geigy Corp.). 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof. EP 122232, ES 8602846, ES 8705459, ES 8705461, JP 84231100, US 4559332.
5. Swedberg, K., Eneroth, P., Kjekshus, J., Wilhelmsen, L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990, 82: 1730-6.
6. Lombes, M., Oblin, M.E., Gasc, J.M., Baulieu, E.E., Farman, N., Bonvalet, J.P. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992, 71: 503-10.
7. Lombes, M., Farman, N., Oblin, M.E., Baulieu, E.E., Bonvalet, J.P., Erlanger, B.F., Gasc, J.M. Immunohistochemical localization of renal mineralocorticoid receptor by using an anti-idiotypic antibody that is an internal image of aldosterone. Proc Natl Acad Sci USA 1990, 87: 1086-8.
8. Weber, K.T., Brilla, C.G. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991, 83: 1849-65.
9. Bauwens, F.R., Duprez, D.A., De Buyzere, M.L., De Backer, T.L., Kaufman, J.M., Van Hoecke, J., Vermeulen, A., Clement, D.L. Influence of the arterial blood pressure and nonhemodynamic factors on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1991, 68: 925-9.
10. Delyani, J.A. Anti-aldosterone therapy in the treatment of heart failure. IBC 3rd Annu Int Conf Heart Failure (Dec 11-12, Philadelphia) 1997.
11. Delyani, J.A. Anti-aldosterone therapy in the treatment of heart failure: New thoughts on an old hormone. Exp Opin Invest Drugs 1998, 7: 753-9.
12. Brilla, C.G., Matsubara, L.S., Weber, K.T. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993, 25: 563-75.
13. Pitt, D. ACE inhibitor co-therapy in patients with heart failure: Rationale for the Randomized Aldactone Evaluation Study (RALES). Eur Heart J 1995, 16(Suppl. N): 107-10.
14. De Gasparo, M., Joss, U., Ramjoué, H.P. et al. Three new epoxy-spirolactone derivatives: Characterization in vivo and in vitro. J Pharmacol Exp Ther 1987, 240: 650-6.
15. Delyani, J., Myles, K., Funder, J. Eplerenone (SC 66110), a highly selective aldosterone antagonist. Am J Hypertens 1998, 11(4, Part 2): 94A.
16. Frierdich, G., Schuh, J., Brown, M., Nochowiak, D., Blehm, D., Delyani, J.A. Effects of the selective mineralocorticoid receptor antagonist, eplerenone, in a model of aldosterone-induced hypertension and cardiac fibrosis. Am J Hypertens 1998, 11(4, Part 2): 94A.
17. Rocha, R., Chander, P.N., Zuckerman, A., Stier, C.T. Jr. Role of mineralocorticoids in renal injury in stroke-prone hypertensive rats. Hypertension 1998, 32(3): Abst 49.
18. Epstein, M., Menard, J., Alexander, J.C., Roniker, B. Eplerenone, a novel and selective aldosterone receptor antagonist: Efficacy in patients with mild to moderate hypertension. Circulation 1998, 98(17, Suppl.): Abst 498.
19. Epstein, M., Alexander, J.C., Roniker, B. Eplerenone, a new selective aldosterone receptor antagonist (SARA): Efficacy in patients with mild to moderate hypertension. J Am Soc Nephrol 1998, 9: Abst A1640.
20. Pitt, B., Roniker, B. Eplerenone, a novel selective aldosterone receptor antagonist (SARA): Dose finding study in patients with heart failure. J Am Coll Cardiol 1999, 33(2, Suppl. A): 188A.
21. Claire, M., Faraj, H., Grassy, G., Aumelas, A., Rondot, A., Auzou, G. Synthesis of new 11β-substituted spirolactone derivatives. Relationship with affinity for mineralocorticoid and glucocorticoid receptors. J Med Chem 1993, 36: 2404-7.
22. Losert, W., Bittler, D., Buse, M., Casals-Stenzel, J., Haberey, M., Laurent, H., Nickisch, K., Schillinger, E., Wiechert, R. Mespirenone and other 15,16-methylene-17-spirolactones, a new type of steroidal aldosterone antagonists. Arzneim-Forsch Drug Res 1986, 36: 1583-600.
23. Casals-Stenzel, J., Buse, M., Wambach, G., Losert, W. The renal action of spirorenone and other 6β,7β; 15β, 16β-dimethylene-17-spirolactones, a new type of steroidal aldosterone antagonists. Arzneim-Forsch Drug Res 1984, 34: 241-6.
24. Sutanto, W., De Kloet, E.R. ZK91587: A novel synthetic antimineralocorticoid displays high affinity for corticosterone (type I) receptors in the rat hippocampus. Life Sci 1988, 43: 1537-43.